

***Fiscal Year 2025 Department of Defense Ovarian Cancer Research Program (OCRP)
Reference Table of Award Mechanisms and Submission Requirements***

Award Mechanism	Eligibility	Key Mechanism Elements	Funding	Submission Deadline
<p>Investigator-Initiated Research Award</p> <p>Go to:</p> <ul style="list-style-type: none"> • Program Announcement • General Application Instructions <p>Grants.gov Funding Opportunity Number: HT942525OCRPIIRA</p>	<p>Investigators at or above the level of Assistant Professor (or equivalent).</p>	<p>Supports high-impact research that addresses a critical need and has the potential to make an important contribution to ovarian cancer or patient/survivor care.</p> <ul style="list-style-type: none"> • Research aimed at extending the lives of advanced state and recurrent patients is encouraged. • If cell lines or animals are used, justification for use is required. • Preliminary data are required. • Clinical trials are not allowed. • Partnering Principal Investigator Option: Up to two investigators may collaborate on a single application, each of whom will be recognized as a Principal Investigator (PI) and receive a separate award. <p><i>Preproposal submission is required; application submission is by invitation only.</i></p>	<ul style="list-style-type: none"> • The maximum allowable funding for the entire period of performance is: <ul style="list-style-type: none"> ○ \$1,050,000 for total costs (direct + indirect costs) for a single PI ○ \$1,400,000 for total costs (direct + indirect costs) for Partnering PIs • The maximum period of performance is 4 years. 	<p>Pre-Application (Preproposal): June 12, 2025 5:00 p.m. Eastern Time (ET)</p> <p>Application: September 11, 2025 11:59 p.m. ET</p>

Award Mechanism	Eligibility	Key Mechanism Elements	Funding	Submission Deadline
<p>Ovarian Cancer Clinical Trial Academy – Early-Career Investigator Award</p> <p>Go to:</p> <ul style="list-style-type: none"> • Program Announcement • General Application Instructions <p>Grants.gov Funding Opportunity Number:</p> <p>HT942525OCRPOCCTAECI</p>	<p>Investigators must be within 12 years of their last postdoctoral research position (Ph.D.), clinical fellowship (M.D.), or equivalent at the time of full application submission deadline. A letter attesting to eligibility is required.</p>	<p>Supports the addition of new early-career investigators (ECIs) to the unique, interactive virtual Clinical Trial Academy that provide intensive mentoring, national networking, collaborations and a peer group for junior faculty.</p> <ul style="list-style-type: none"> • Research will support translational research and small-scale, early-phase clinical trials in ovarian cancer. • ECIs whose ability to commit to conducting ovarian cancer research is limited by lack of resources or other overwhelming obstacles are encouraged to apply. • A Designated Mentor with clinical trial experience and an active clinical trial is required. • A Designated Mentor may mentor only one ECI. • The Designated Mentor is not required to be at the same institution as the ECI. • Preliminary data are required. • Clinical trials are allowed. <p><i>Preproposal submission is required; application submission is by invitation only.</i></p>	<ul style="list-style-type: none"> • The maximum allowable funding for the entire period of performance is \$1,400,000 for total costs (direct + indirect costs). • The maximum period of performance is 4 years. 	<p>Pre-Application (Preproposal): June 12, 2025 5:00 p.m. ET</p> <p>Application: September 11, 2025 11:59 p.m. ET</p>
<p>Pilot Award</p> <p>Go to:</p> <ul style="list-style-type: none"> • Program Announcement • General Application Instructions <p>Grants.gov Funding Opportunity Number:</p> <p>HT942525OCRPPA</p>	<p>Investigators at the level of postdoctoral fellow or clinical fellow (or equivalent).</p>	<p>Supports innovative, high-risk/high-reward research in ovarian cancer that could ultimately lead to critical discoveries or major advancements that will drive the field forward.</p> <ul style="list-style-type: none"> • Innovation is an important review criterion. • The goal is to develop preliminary data; thus, preliminary data are not required, but are allowed. • Research aimed at extending the lives of advanced-state and recurrent patients is encouraged. • Clinical trials are not allowed. • Early Detection or Prevention Option: This option supports research that focuses on innovative concepts or theories leading to major advances in the fields of early ovarian cancer detection or ovarian cancer prevention. • Reviewers will be blinded to the identity of the PI, collaborators and their organization(s) <p><i>Preproposal submission is required; application submission is by invitation only.</i></p>	<ul style="list-style-type: none"> • The maximum allowable funding for the entire period of performance is \$350,000 for total costs (direct + indirect costs). • The maximum period of performance is 2 years. 	<p>Pre-Application (Preproposal): June 12, 2025 5:00 p.m. ET</p> <p>Application: September 11, 2025 11:59 p.m. ET</p>